Surgical treatment of oligometastatic non-small cell lung cancer - PubMed (original) (raw)
Review
Surgical treatment of oligometastatic non-small cell lung cancer
Joachim Pfannschmidt et al. Lung Cancer. 2010 Sep.
Abstract
Patients with stage IV metastatic non-small cell lung cancer (NSCLC) are generally believed to have an incurable disease. Patients with oligometastatic disease represent a distinct subset of patients among those with metastatic disease. There is evidence that these patients have synchronous or metachronous satellite nodules in different pulmonary lobes or have solitary extrapulmonary metastases. In these cases, evidence has shown that surgical resection may provide patients with survival benefit. This article discusses the biology of the oligometastatic state in patients with lung cancer and the selection of patients for surgery, as well as the prognostic factors that influence survival of the patient. To properly select patients for an aggressive local treatment regime, accurate clinical staging is of prime importance. The use of FDG-PET should be considered for restaging if oligometastatic disease is suspected based on a patient's CT scan. A limitation of retrospective clinical studies for oligometastatic disease is that it is difficult to summarize and evaluate the available evidence for the effectiveness of surgical resection due to selection bias, and to a high degree of variability among different clinical studies. Nevertheless, we can certainly learn from the clinical experience acquired from retrospective case series to identify prognostic factors. Following surgical resection, the overall 5-year actuarial survival rate is about 28% for patients with satellite nodules and 21% for patients with ipsilateral nodules. Patients with resected brain metastasis achieve 5-year survival rates between 11% and 30%, and those with adrenalectomy for adrenal metastasis achieve 5-year survival rates of 26%.
Copyright (c) 2010 Elsevier Ireland Ltd. All rights reserved.
Similar articles
- Non-small cell lung cancer with a solitary hematogenous metastasis.
Downey RJ. Downey RJ. Thorac Surg Clin. 2004 May;14(2):265-9, vii-viii. doi: 10.1016/S1547-4127(04)00003-9. Thorac Surg Clin. 2004. PMID: 15382302 - Surgical treatment of primary lung cancer with synchronous brain metastases.
Billing PS, Miller DL, Allen MS, Deschamps C, Trastek VF, Pairolero PC. Billing PS, et al. J Thorac Cardiovasc Surg. 2001 Sep;122(3):548-53. doi: 10.1067/mtc.2001.116201. J Thorac Cardiovasc Surg. 2001. PMID: 11547308 - Results of a surgical resection for patients with stage IV non--small-cell lung cancer.
Hanagiri T, Takenaka M, Oka S, Shigematsu Y, Nagata Y, Shimokawa H, Uramoto H, Tanaka F. Hanagiri T, et al. Clin Lung Cancer. 2012 May;13(3):220-4. doi: 10.1016/j.cllc.2011.05.006. Epub 2011 Dec 3. Clin Lung Cancer. 2012. PMID: 22138036 - Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature.
Bastian S, Clerici T, Neuweiler J, Cerny T, Früh M. Bastian S, et al. Onkologie. 2011;34(12):665-70. doi: 10.1159/000334541. Epub 2011 Nov 21. Onkologie. 2011. PMID: 22156445 Review. - [The boundaries of curation].
Debus J, Eberhardt W, Hoffmann H, Passlick B, Rübe C, Thomas M. Debus J, et al. Onkologie. 2010;33 Suppl 5:12-20. doi: 10.1159/000313972. Epub 2010 May 14. Onkologie. 2010. PMID: 20523102 Review. German.
Cited by
- Molecular determinants of lung cancer metastasis to the central nervous system.
Whitsett TG, Inge LJ, Dhruv HD, Cheung PY, Weiss GJ, Bremner RM, Winkles JA, Tran NL. Whitsett TG, et al. Transl Lung Cancer Res. 2013 Aug;2(4):273-83. doi: 10.3978/j.issn.2218-6751.2013.03.12. Transl Lung Cancer Res. 2013. PMID: 25806243 Free PMC article. Review. - Exploring the microRNA profiles as potential diagnostic probes for oligo- and polymetastatic prognosis of lung metastasis(es) patients.
Wang Z, Gao S, Li T, Ma X, Zhu H, Yan H. Wang Z, et al. Medicine (Baltimore). 2018 Jun;97(23):e10958. doi: 10.1097/MD.0000000000010958. Medicine (Baltimore). 2018. PMID: 29879044 Free PMC article. - The consideration of surgery on primary lesion of advanced non-small cell lung cancer.
Ren J, Ren J, Wang K, Tan Q. Ren J, et al. BMC Pulm Med. 2023 Apr 14;23(1):118. doi: 10.1186/s12890-023-02411-w. BMC Pulm Med. 2023. PMID: 37060050 Free PMC article. - Developments in oligometastatic hormone-sensitive prostate cancer.
Chow K, McCoy P, Stuchbery R, Corcoran NM, Hovens CM. Chow K, et al. World J Urol. 2019 Dec;37(12):2549-2555. doi: 10.1007/s00345-018-2542-x. Epub 2018 Oct 31. World J Urol. 2019. PMID: 30382379 - Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study.
Zhang JT, Liu SY, Yan HH, Wu YL, Nie Q, Zhong WZ. Zhang JT, et al. BMC Cancer. 2019 Nov 6;19(1):1051. doi: 10.1186/s12885-019-6216-x. BMC Cancer. 2019. PMID: 31694572 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical